CD8A and neoplasm: Interestingly, although there was no difference in the efficacy and CD8 T cell infiltration between the monotherapy and combination therapy groups (Figure 7B), the number of tumor antigen-specific CD8 T cells in the combination group increased compared to that in the Q702 or anti-PD-1 antibody monotherapy groups (Figure 7C).